Oncology Institute (NASDAQ:TOI) Research Coverage Started at B. Riley

B. Riley initiated coverage on shares of Oncology Institute (NASDAQ:TOI) in a research report sent to investors on Wednesday, MarketBeat reports. The firm issued a buy rating and a $6.00 target price on the stock. B. Riley also issued estimates for Oncology Institute’s Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.55) EPS and FY2025 earnings at ($0.55) EPS.

Separately, BTIG Research started coverage on shares of Oncology Institute in a report on Thursday, May 15th. They set a “buy” rating and a $7.00 price target for the company.

Oncology Institute Stock Down 4.1%

TOI stock opened at $3.50 on Wednesday. The company has a debt-to-equity ratio of 14.58, a current ratio of 1.79 and a quick ratio of 1.59. Oncology Institute has a 1-year low of $0.13 and a 1-year high of $3.78. The firm has a fifty day moving average price of $2.74 and a two-hundred day moving average price of $1.75. The firm has a market cap of $312.31 million, a price-to-earnings ratio of -5.00 and a beta of 0.02.

Oncology Institute (NASDAQ:TOI) last released its earnings results on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter. Oncology Institute had a negative net margin of 15.38% and a negative return on equity of 445.02%. The business had revenue of $104.41 million for the quarter.

Insider Buying and Selling at Oncology Institute

In other news, Director Brad Hively sold 1,976,137 shares of the business’s stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $2.87, for a total transaction of $5,671,513.19. Following the completion of the transaction, the director owned 603,501 shares of the company’s stock, valued at approximately $1,732,047.87. The trade was a 76.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Growth I. L.P. M33 sold 1,796,468 shares of the company’s stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $2.71, for a total transaction of $4,868,428.28. Following the completion of the sale, the director directly owned 14,624,233 shares of the company’s stock, valued at $39,631,671.43. The trade was a 10.94% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 4,726,137 shares of company stock valued at $13,379,013. Corporate insiders own 8.50% of the company’s stock.

Institutional Investors Weigh In On Oncology Institute

Several institutional investors have recently bought and sold shares of the stock. Josh Arnold Investment Consultant LLC acquired a new stake in Oncology Institute in the first quarter worth about $2,267,000. FreeGulliver LLC lifted its holdings in Oncology Institute by 219.3% in the fourth quarter. FreeGulliver LLC now owns 600,747 shares of the company’s stock worth $186,000 after purchasing an additional 412,578 shares during the period. Renaissance Technologies LLC lifted its holdings in Oncology Institute by 7.1% in the fourth quarter. Renaissance Technologies LLC now owns 182,000 shares of the company’s stock worth $56,000 after purchasing an additional 12,000 shares during the period. Virtu Financial LLC acquired a new stake in Oncology Institute in the fourth quarter worth about $41,000. Finally, Jane Street Group LLC lifted its holdings in Oncology Institute by 613.6% in the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock worth $39,000 after purchasing an additional 109,769 shares during the period. Institutional investors and hedge funds own 36.86% of the company’s stock.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.